Latest News in the pharma Industry
Research & Development
Zymeworks and Innovative Targeting Solutions enter collaboration and license agreement to advance biotherapeutics R&D
13 Aug 2016
Collaboration will use HuTARG - a first-in-class protein engineering platform.
Read more
Arch Biopartners engages Catalent to begin manufacturing process for AB569
13 Aug 2016
Preparations underway for the first human trials involving patients with antibiotic resistant lung infections.
Read more
Lilly to continue trial of abemaciclib and fulvestrant combo for breast cancer
11 Aug 2016
Following interim analysis, a DMC recommends the study to continue without modification.
Read more
ADDC and AstraZeneca announce third year of screening partnership
10 Aug 2016
Partnership facilitates efforts by researchers from academia to discover novel compounds with the potential to become new patient treatments.
Read more
Veritas reaches important scientific milestone
10 Aug 2016
Animal studies fully underway to evaluate the safety and effectiveness of cannabis strains.
Read more
University of Pittsburgh licenses novel microneedle patch to SkinJect
9 Aug 2016
SkinJect Microneedle Patch to deliver drug to treat and immunize skin cancer patients.
Read more
Charles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium
9 Aug 2016
Through this partnership, the academic institutions in the Consortium will have access to Charles River’s early discovery and drug development resources and services to accelerate their early-stage drug development processes.
Read more
FDA approves Merck’s Keytruda for patients with recurrent or metastatic HNSCC
7 Aug 2016
New treatment option for patients with with disease progression on or after platinum-containing chemotherapy.
Read more
BMS CheckMate -26 trial fails to meet primary endpoint
7 Aug 2016
Opdivo did not meet trial primary endpoint of progression-free survival in patients expressing PD-L1 ≥ 5%.
Read more
Regeneron and Adicet Bio collaborate to discover and develop next-generation engineered immune cell therapeutics
3 Aug 2016
Companies to pursue "off-the-shelf" cellular therapies in oncology.
Read more
Catalent Biologics and Zumutor collaborate to develop antibodies with enhanced ADCC Activity
2 Aug 2016
The partnership created a fucose knockout GPEx cell line expressing high levels of an anti-HER2 antibody.
Read more
Selecta Biosciences describes novel approach for improving the efficacy and safety profile of biologic drugs
1 Aug 2016
The data support Selecta’s lead clinical program, showing Selecta’s SVP-Rapamycin (SEL-110) induces antigen-specific immune tolerance and prevents the formation of anti-drug antibodies to biologic drugs, including pegsiticase (for gout) and adalimumab ...
Read more